Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | UTS2R | Q9UKP6 | 9/20 | 0.48 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | DRD4 | P21917 | 4/20 | 0.44 |
| ▸ | DRD3 | P35462 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1471914 | 0.83 | MAPT (0.53) | MAPTNPSR1TDP1L3MBTL1UTS2R | |
| SCHEMBL1472402 | 0.70 | UTS2R (0.58) | MAPTNPSR1TDP1L3MBTL1UTS2R | |
| SCHEMBL1471912 | 0.68 | UTS2R (0.58) | MAPTNPSR1TDP1L3MBTL1UTS2R | |
| SCHEMBL1472368 | 0.67 | UTS2R (0.57) | MAPTNPSR1TDP1L3MBTL1UTS2R | |
| SCHEMBL1472806 | 0.65 | UTS2R (0.72) | MAPTNPSR1TDP1L3MBTL1UTS2R | |
| SCHEMBL1732466 | 0.65 | UTS2R (0.82) | MAPTNPSR1TDP1L3MBTL1UTS2R | |
| SCHEMBL1472930 | 0.65 | UTS2R (1.00) | MAPTNPSR1TDP1L3MBTL1UTS2R | |
| SCHEMBL9050818 | 0.64 | KMT2A (0.44) | MAPTNPSR1TDP1L3MBTL1DRD2 | |
| SCHEMBL1732461 | 0.64 | UTS2R (0.53) | MAPTNPSR1TDP1L3MBTL1UTS2R | |
| SCHEMBL4202385 | 0.63 | MAPT (0.63) | MAPTNPSR1TDP1L3MBTL1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | claimed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | claimed |
| US-8536174-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | disclosed |
| US-8193191-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-05 | — | — | US | disclosed |
| EP-1993554-B1 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-23 | — | — | EP | disclosed |
| US-20110136824-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E | 2011-06-09 | — | — | US | disclosed |
| US-7915260-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-03-29 | — | — | US | disclosed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, BDKRB2 | MAPT 2181/4885NPSR1 122/4885TDP1 3396/4885 |
| US-20070191391-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, BDKRB2 | MAPT 2181/4885NPSR1 122/4885TDP1 3396/4885 |
| US-20110136824-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, BDKRB2 | MAPT 2181/4885NPSR1 122/4885TDP1 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.